The stock of PDS Biotechnology Corporation (NASDAQ:PDSB) is now priced at $3.89 and the shares are 0.31 points up or 8.66% higher compared to its previous closing price of $3.58. PDSB shares have a float of 9.77 million and although its performance was -7.16% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the PDSB share price recently placing at $3.45 to $3.88. However, some brokerage firms have priced the stock below the average, including one that has called $4.
The shorts are climbing into the PDS Biotechnology Corporation stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the PDSB shares have risen. Short interest in the stock represents just 6.91% of its float, but the volume has raised by 497414. The volume of shorted shares rised to 675180 from 177766 shares over the last two weeks. The average intraday trading volume has been 1.564 million shares, which means that days to cover moved to roughly 1.
In the last trading session, PDS Biotechnology Corporation (NASDAQ:PDSB) dropped by -$0.3 over the week and gained $2.27 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $6.71. The stock recorded its established 52-week high on 07/30/19.
Since 04/02/20, the stock has traded to a low of $0.62 at 532.21%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 3.2. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, PDS Biotechnology Corporation’s two-week RSI is 68.03. This suggests that the stock is neutral at the moment and that PDSB shares’ price movement remains stable. The stochastic readings are equally revealing at 72.16% meaning the PDSB share price is currently in oversold territory.
The technical chart shows that the PDSB stock will likely settle at between $4.38 and $4.88 per share. However, if the stock dips below $3.5, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $3.12.
Currently, the stock is trading in the green of MACD, with a reading of 0.3. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned PDSB a rating of Buy in their intiating review released on May 27. Noble Capital Markets analysts see the stock as a Outperform with a target price of $5.45 in a flash note released to investors on March 09 initiating covering the stock. Chardan Capital Markets analysts see the stock as Buy when the analysts initiated the share price coverage on October 24, placing it at $10.
The average rating for the PDSB equity is 2.25 and is currently gathering a bullish momentum. Of 4 analysts tracking PDS Biotechnology Corporation polled by Reuters, 1 rated PDSB as a hold. The remaining 3 analysts were split evenly. However, the split wasn’t equal as a majority (3) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the PDSB stock price is 299.23X ahead of its 12-month Consensus earnings per share estimates.